ArticleArchives of microbiology2026
Immunomodulatory effect of Lacticaseibacillus rhamnosus and Lactobacillus acidophilus in human dendritic cells.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study explored the immunomodulatory properties of the probiotic strains Lacticaseibacillus rhamnosus LR-32 and Lactobacillus acidophilus LA-5 by evaluating their effects on human dendritic cell (DC) responses. Immature DCs were obtained from human CD14⁺ monocytes and challenged with E. coli LPS and/or probiotic lactobacilli at a DC ratio of 1:10. Relative transcription of inflammatory mediators and pattern-recognition receptors was assessed by RT-qPCR. Cytokine production and surface marker expression were evaluated by ELISA and flow cytometry, respectively. DC function was further assessed after interaction with CD4⁺ T lymphocytes, followed by analysis of T cell phenotype by flow cytometry and cytokine production by ELISA. LPS upregulated the transcription of intracellular receptors AIM2, NOD1, and NOD2 and increased COX-2, TNF-α, IL-1β, IL-6, CXCL-8, IL-12, and IL-18 mRNA levels compared with immature DCs (p < 0.001). Exposure to probiotics downregulated most genes encoding receptors and inflammatory mediators compared with LPS-stimulated DCs. In LPS-stimulated DCs, LA-5 reduced intra- and extracellular receptor gene expression, increased COX-2, TNF-α, IL-1β, IL-6, CXCL-8, and IL-10 transcription, and decreased IL-12 mRNA levels. LR-32 upregulated TLR2, COX-2, IL-6, CXCL-8, and IL-10, while reducing IL-12 expression, although these effects were less pronounced than those induced by LA-5. LA-5-exposed DCs induced a higher frequency of CD25highFOXP3highCD127low CD4⁺ T cells than LR-32. These findings indicate that LA-5 and LR-32 modulate human DC responses in a strain-dependent manner. Rather than acting as broadly anti-inflammatory stimuli, these probiotics reshaped LPS-induced activation by modulating pattern-recognition receptor pathways, cytokine responses, and a Treg-associated CD4⁺ T cell phenotype, suggesting a potential role in controlled mucosal immune regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.